Stockreport

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of [Read more]